- Home
- PEN
PEN
Penumbra Inc.
as 12-20-2024 3:41pm EST
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 7.0B | IPO Year: | 2015 |
| Target Price: | $259.86 | AVG Volume (30 days): | 337.8K |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.89 | EPS Growth: | -15.96 |
| 52 Week Low/High: | $148.00 - $277.34 | Next Earning Date: | 10-30-2024 |
| Revenue: | $1,163,776,000 | Revenue Growth: | 16.96% |
| Revenue Growth (this year): | 13.65% | Revenue Growth (next year): | 14.38% |
Stock Insider Trading Activity of Penumbra Inc. (PEN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Dec 2 '24 | Sell | $243.88 | 600 | $146,696.56 | 64,008 | |
| Shiu Lambert | PEN | Chief Accounting Officer | Nov 29 '24 | Sell | $242.79 | 2,452 | $595,051.42 | 20,028 | |
| Elsesser Adam | PEN | CEO and President | Nov 20 '24 | Sell | $237.22 | 15,000 | $3,559,175.51 | 855,863 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Nov 15 '24 | Sell | $238.99 | 600 | $143,842.87 | 64,008 | |
| Elsesser Adam | PEN | CEO and President | Oct 21 '24 | Sell | $204.71 | 15,000 | $3,068,366.75 | 855,863 | |
| Grewal Harpreet | PEN | Director | Oct 2 '24 | Sell | $190.83 | 166 | $31,677.78 | 8,697 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Oct 1 '24 | Sell | $191.07 | 600 | $114,455.67 | 64,008 | |
| Kassing Don W. | PEN | Director | Oct 1 '24 | Sell | $193.93 | 170 | $32,968.10 | 835 |
Latest Penumbra Inc. News
PEN Breaking Stock News: Dive into PEN Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2025
TipRanks
3 days ago
Penumbra price target raised to $285 from $240 at Truist
Argus Research
4 days ago
PEN: Raising target price to $204.00
Argus Research
11 days ago
PEN: Lowering target price to $202.00
Zacks
12 days ago
Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why
Zacks
16 days ago
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
Simply Wall St.
18 days ago
Investing in Penumbra (NYSE:PEN) five years ago would have delivered you a 55% gain
Argus Research
18 days ago
PEN: Lowering target price to $203.00
Compare PEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PEN Penumbra Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.